The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies
<h4>Background</h4> The private versus public contribution to developing new health knowledge and interventions is deeply contentious. Proponents of commercial innovation highlight its role in late-stage clinical trials, regulatory approval, and widespread distribution. Proponents of pub...
Enregistré dans:
Auteurs principaux: | , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bbdf4ba2572e407d8c7e6934c1427eef |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|